These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36302669)

  • 21. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
    Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
    Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease.
    Laforêt P; Laloui K; Granger B; Hamroun D; Taouagh N; Hogrel JY; Orlikowski D; Bouhour F; Lacour A; Salort-Campana E; Penisson-Besnier I; Sacconi S; Zagnoli F; Chapon F; Eymard B; Desnuelle C; Pouget J;
    Rev Neurol (Paris); 2013; 169(8-9):595-602. PubMed ID: 24008051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential patient screening for late-onset Pompe disease in suspected sleep apnea: a rationale and study design for a Prospective Multicenter Observational Cohort Study in Japan (PSSAP-J Study).
    Yamauchi M; Nakayama H; Shiota S; Ohshima Y; Terada J; Nishijima T; Kosuga M; Kitamura T; Tachibana N; Oguri T; Shirahama R; Aoki Y; Ishigaki K; Sugie K; Yagi T; Muraki H; Fujita Y; Takatani T; Muro S
    Sleep Breath; 2021 Jun; 25(2):695-704. PubMed ID: 32808237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
    Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
    J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for late-onset Pompe disease in western Denmark.
    Hansen JS; Pedersen EG; Gaist D; Bach FW; Vilholm OJ; Sandal B; Weitemeyer L; Nielsen K; Schlesinger FE; Preisler N; Vissing J; Andersen H
    Acta Neurol Scand; 2018 Jan; 137(1):85-90. PubMed ID: 28832912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
    Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
    Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Six-Minute Walk Distance Is a Useful Outcome Measure to Detect Motor Decline in Treated Late-Onset Pompe Disease Patients.
    Claeys KG; D'Hondt A; Fache L; Peers K; Depuydt CE
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease-a long-term follow-up.
    Andreassen CS; Schlütter JM; Vissing J; Andersen H
    Mol Genet Metab; 2014 May; 112(1):40-3. PubMed ID: 24685124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
    Vanherpe P; Fieuws S; D'Hondt A; Bleyenheuft C; Demaerel P; De Bleecker J; Van den Bergh P; Baets J; Remiche G; Verhoeven K; Delstanche S; Toussaint M; Buyse B; Van Damme P; Depuydt CE; Claeys KG
    Orphanet J Rare Dis; 2020 Apr; 15(1):83. PubMed ID: 32248831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased inspiratory and expiratory muscle strength following respiratory muscle strength training (RMST) in two patients with late-onset Pompe disease.
    Jones HN; Moss T; Edwards L; Kishnani PS
    Mol Genet Metab; 2011 Nov; 104(3):417-20. PubMed ID: 21641843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole-body magnetic resonance imaging in late-onset Pompe disease: Clinical utility and correlation with functional measures.
    Khan AA; Boggs T; Bowling M; Austin S; Stefanescu M; Case L; Kishnani PS
    J Inherit Metab Dis; 2020 May; 43(3):549-557. PubMed ID: 31710733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
    Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
    Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.
    Napolitano F; Bruno G; Terracciano C; Franzese G; Palomba NP; Scotto di Carlo F; Signoriello E; De Blasiis P; Navarro S; Gialluisi A; Melone MAB; Sampaolo S; Esposito T
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Seven Novel Mutations in the Acid Alpha-glucosidase Gene in Five Chinese Patients with Late-onset Pompe Disease.
    Liu HX; Pu CQ; Shi Q; Zhang YT; Ban R
    Chin Med J (Engl); 2018 Feb; 131(4):448-453. PubMed ID: 29451150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy.
    Pascarella A; Terracciano C; Farina O; Lombardi L; Esposito T; Napolitano F; Franzese G; Panella G; Tuccillo F; la Marca G; Bernardini S; Boffo S; Giordano A; Di Iorio G; Melone MAB; Sampaolo S
    J Cell Physiol; 2018 Aug; 233(8):5829-5837. PubMed ID: 29215735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tongue weakness and atrophy differentiates late-onset Pompe disease from other forms of acquired/hereditary myopathy.
    Jones HN; Hobson-Webb LD; Kuchibhatla M; Crisp KD; Whyte-Rayson A; Batten MT; Zwelling PJ; Kishnani PS
    Mol Genet Metab; 2021 Jul; 133(3):261-268. PubMed ID: 34053870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Case of Adult-onset Pompe Disease with Cerebral Stroke and Left Ventricular Hypertrophy.
    Hossain MA; Miyajima T; Akiyama K; Eto Y
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3046-3052. PubMed ID: 30093193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic tools in late onset Pompe disease (LOPD).
    Musumeci O; Toscano A
    Ann Transl Med; 2019 Jul; 7(13):286. PubMed ID: 31392198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function.
    Gaeta M; Barca E; Ruggeri P; Minutoli F; Rodolico C; Mazziotti S; Milardi D; Musumeci O; Toscano A
    Mol Genet Metab; 2013 Nov; 110(3):290-6. PubMed ID: 23916420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.